Evofem and Aditxt Merger Expected to Gain Stockholder Approval Soon

Evofem and Aditxt Merger Anticipated to Receive Stockholder Approval

Evofem Biosciences, Inc. is on track for a significant milestone as it prepares for a stockholder meeting scheduled for September 26, 2025. The primary agenda at this Special Meeting is to secure approval for its merger with Aditxt, Inc. and its wholly-owned subsidiary, Adifem, Inc. This merger aims to bolster Evofem's position in the women's healthcare sector, leveraging Aditxt's resources for better innovation and outreach.

CEO Saundra Pelletier expressed optimism surrounding the upcoming vote, highlighting the backing of key investors, primarily the holders of Series E-1 and G-1 stock. Their support is crucial, as it constitutes 53.71% of the combined voting power necessary for a successful approval of the merger. Past voting agreements bolster confidence that these stockholders will indeed follow through as expected, though there are no guarantees.

The merger proposal is laid out in detail in the Definitive Proxy filed with the U.S. Securities and Exchange Commission on September 8, 2025. According to this document, the merger is predicated on the successful acquisition of at least a majority vote from the combined stockholder groups. If approved and all conditions are met, Evofem will emerge as a wholly-owned subsidiary of Aditxt, becoming the foundation of a dedicated women’s health initiative as part of Aditxt's broader social innovation platform.

Evofem is steadfast in its mission to empower women through innovative products aimed at unaddressed needs in sexual and reproductive health. It has successfully brought to market FDA-approved products such as PHEXXI®, the first and only hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC®, a single-dose oral treatment for bacterial vaginosis and trichomoniasis. These products showcase Evofem's commitment to women's health and underline its ambitions going forward after the merger.

As the date of the Special Meeting approaches, stockholders must fully digest the information shared in the Definitive Proxy. It emphasizes the significance of their vote and details the conditions under which the merger would take place. Approval hinges on the support of existing Series E-1 and G-1 shareholders, who together represent a substantial portion of voting power. The outcome of the meeting holds promise for a transformative shift in the direction of Evofem's operations, paving the way for expanded resources and innovative healthcare solutions for women.

In conclusion, the anticipated merger between Evofem and Aditxt may prove pivotal for the company as it seeks to enhance its commitment to delivering revolutionary healthcare products for women. The results of the stockholder meeting will greatly determine how quickly they can implement these changes and forge ahead into a new chapter of growth and innovation in women's sexual and reproductive health. Stakeholders and onlookers alike will be watching closely to see if this merger receives the affirmative vote it requires by September 26, 2025.